Resveratrol from red grapes - Pedestrian polyphenol or useful anticancer agent?

Planta Medica

Volumn 74, Issue 13, 2008, Pages 1651-1655

  Gescher, Andreas J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Analogues; Caloric restriction; Cancer chemoprevention; Resveratrol

Indexed keywords

3,3',4',5 TETRAHYDROXYSTILBENE; ANTINEOPLASTIC AGENT; CIS 3,4',5 TRIMETHOXY 3' AMINOSTILBENE; CIS 3,4',5 TRIMETHOXY 3' HYDROXYSTILBENE; CYTOTOXIC AGENT; DAUNORUBICIN; DRUG METABOLIZING ENZYME; POLYPHENOL; PTEROSTILBENE; RESVERATROL; STILBENE DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CALORIC RESTRICTION; CELL CYCLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; ENZYME INHIBITION; GRAPE; HUMAN; NONHUMAN; REVIEW; SINGLE DRUG DOSE;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; MOLECULAR STRUCTURE; STILBENES; VITIS;

RODENTIA; VITACEAE;

EID: 56249106569     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1074516     Document Type: Review

References (54)

1. Siemann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Eno Vitic 1992; 43: 49-52
2. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-20
3. Gescher AJ, Steward WP. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: A conundrum. Cancer Epidemiol Biomarkers Prev 2003; 12: 953-7
4. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5:493-506
5. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005; 49: 472-81
6. Aggarwal BB, Shishodia S. Resveratrol in health and disease Boca Raton, FL: CRC Press, Taylor and Francis Group; 2006
7. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E et al. Suppression of intestinal polyposis in Apc5716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-9
8. Li ZG, Hong T, Shimada Y, Komoto I, Kawabe A, Ding Y et al. Suppression of N-nitroso-methylbenzylamine (NMBA)-induced esophagael tumourigenesis in F344 rats by resveratrol. Carcinogenesis 2002; 23: 1531-6
9. Aziz M, Afaq F, Ahmad N. Prevention of ultraviolet-B radiation damage by resveratrol in mouse skin is mediated via modulation in survivin. Photochem Photobiol 2004; 81: 25-31
10. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998; 273: 21875-82
11. Martin AR, Villegas I, La Casa C, de la Lastra CA. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 2004; 67: 1399-1410
12. Kimura Y, Okuda H. Resveratrol isolated from Polygonuum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularisation in Lewis lung carcinoma-bearing mice. J Nutr 2001; 131: 1844-9
13. Tseng SH, Lin SM, Chen JC, Su YH, Huang HY, Chen CK et al. Resveratrol suppresses theangiogenesisand tumor growth of gliomas in rats. Clin Cancer Res 2004; 10: 2190-2
14. Yu C, Shin YG, Kosmeder JW, Pezzuto JM, van Breemen RB. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun Mass Spectrom 2003; 17: 307-13
15. Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001; 125: 83-91
16. Chang TK, Lee WB, Ko HH. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. Can J Physiol Pharmacol 2000; 78: 874-81
17. Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000; 67: 3103-12
18. Cao Z, Li Y. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur J Pharmacol 2004; 489: 39-48
19. Sengottuvelan M, Viswanathan P, Nalini N. Chemopreventive effect of trans-resveratrol - a phytoalexin against colonie aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis 2005; 27: 1038-46
20. Miura D, Miura Y, Yagasaki K. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci 2003; 73: 1393-400
21. Wenzel E, Soldo T, Erbersdobler H, Somoza V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 2005; 49: 482-94
22. Clement MV, Hirpara JL, Chawdhury SH, Pervaiz S. The chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998; 92: 996-1002
23. Yu L, Sun ZJ, Wu SK, Pan CE. Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer. World J Castroenterol 2003; 9: 2341-3
24. Schneider Y, Duranton B, Gosse F, Schleiffer R, Seiler N, Raul F. Resveratrol inhibits intestinal tumourigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer 2001; 39: 102-7
25. Reagan-Shaw S, Afaq F, Aziz MH, Ahmad N. Modulation of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-I hairless mouse skin. Oncogene 2004; 23: 5151-60
26. Garvin S, Ollinger K, Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 2006; 231: 113-22
27. Provinciali M, Re F, Donnini A, Orlando F, Bartozzi B, Di Stasio Get al. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer 2005; 115: 36-45
28. Zhou HB, Chen JJ, Wang WX, Cai JT, Du Q. Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol 2005; 11: 280-4
29. Fulda S, Debatin KM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004; 64: 337-46
30. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-42
31. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F et al. Resveratrol improves mitochondria! function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha. Cell 2006; 127: 1109-22
32. Ahmad KA, Clement MV, Hanif IM, Pervaiz S. Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu non-permissive for death execution. Cancer Res 2004; 64: 1452-9
33. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 2002; 320: 369-73
34. Asensi M, Medina I, Ortega A, Carretero J, Bano MC, Obrador E et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002; 33: 387-98
35. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Disp 2004; 32: 1377-82
36. Boocock DJ, Faust GES, Patel KR, Schinas AM, Brown VA, Ducharme MP et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16: 1246-52
37. Meng XF, Maliakal P, Lu H, Lee MJ, Yang CS. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 2004; 52: 935-42
38. Zern TL, Wood RJ, Greene C, West KL, Liu YZ, Aggarwal D et al. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr 2005; 135: 1911-7
39. Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi PP et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 2005; 49: 495-504
40. Goldberg DA, Van J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003; 36: 79-87
41. Zamora-Ros R, Urpi-Sarda M, Lamuela-Raventos RM, Estruch R, Vazquez-Agell M, Serrano-Martinez M et al. Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin Chem 2006; 52: 1373-80
42. Lekakis J, Ralliais LS, Andreadou I, Vamvakou G, Kazantzoglou G, Magiatis P et al. Polyphenolic compunds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005; 12: 596-600
43. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J 2003; 17: 1975-85
44. Russo GL. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol 2007; 74: 533-44
45. Howells LM, Moiseeva EP, Neal CP, Foreman BE, Kandreadi CK, Sun YY et al. Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol Sin 2007; 28: 1274-304
46. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrolassociated renal toxicity. Toxicol Sci 2004; 82: 614-9
47. Pettit GR, Grealish MP, Jung MK, Hamel E, Pettit RK, Chapuis JC et al. Antineoplastic agents. 465. Structural modification of resveratrol: sodium resveratrin phosphate. J Med Chem 2002; 45: 2534-42
48. Kim S, Ko H, Park JE, Jung S, Lee SK, Chun YJ. Design, synthesis and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem 2002; 45: 160-4
49. Thakkar K, Geahlen RL, Cushman M. Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol. J Med Chem 1993; 36: 2950-5
50. Cushman M, Nagarathnam D, Gopal D, He HM, Lin CM, Hamel E. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5- trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents. J Med Chem 1992; 35: 2293-306
51. Heynekamp JJ, Weber WM, Hunsaker LA, Gonzales AM, Orlando RA, Deck LM et al. Substituted trans-stilbenes, including analogues of the natural product resveratrol, inhibit the human tumor necrosis factor alpha-induced activation of transcription factor nuclear factor kappaB. J Med Chem 2006; 49: 7182-9
52. Roberti M, Pizzirani D, Simoni D, Rondanin R, Baruchello R, Bonora C et al. Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents. J Med Chem 2003; 46: 3546-54
53. Murias M, Jager W, Handler N, Erker T, Horvath Z, Szekeres T et al. Antioxidant prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem Pharmacol 2005; 69: 903-12
54. Suh N, Paul S, Hao XP, Simi B, Xiao H, Rimando AM et al. Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats. Clin Cancer Res 2007; 13: 350-5